Drug intelligence / Profile preview

Anti-XX antibody

Development stage: Unknown
Lead developer: Mitsubishi Tanabe Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Anti-XX antibody is a monoclonal antibody developed by **Pharma Foods International (PFI)** in collaboration with **Mitsubishi Tanabe Pharma** for the treatment of autoimmune diseases. The antibody was generated using PFI's proprietary **ALAgene®** technology, which utilizes chicken immunization to produce antibodies against targets that are highly conserved or difficult to address using traditional mammalian platforms. The specific biological target, referred to as 'XX', remains undisclosed by the developers for proprietary reasons. The program entered Phase 1 clinical trials in Japan in 2021 to evaluate safety, tolerability, and pharmacokinetics in healthy subjects.

Other names: 抗XX抗体

Beyond the preview

Go deeper on Anti-XX antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-XX antibody.

Explore the full profile